Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial
- Authors
- Park, Dae Hyun; Chung, Jin Kwon; Seo, Du Ri; Lee, Sung Jin
- Issue Date
- Mar-2016
- Publisher
- Elsevier BV
- Keywords
- Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
- Citation
- American Journal of Ophthalmology, v.163, pp 122 - 131
- Pages
- 10
- Journal Title
- American Journal of Ophthalmology
- Volume
- 163
- Start Page
- 122
- End Page
- 131
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9317
- DOI
- 10.1016/j.ajo.2015.12.002
- ISSN
- 0002-9394
1879-1891
- Abstract
- PURPOSE: To compare the efficacies and safety profiles of 3% diquafosol and 0.1% sodium hyaluronate in patients with dry eye after cataract surgery. DESIGN: Randomized controlled trial. METHODS: SETTING: Soonchunhyang University Hospital, Seoul, South Korea. STUDY POPULATION: In all, 130 eyes of 86 dry eye patients who had undergone cataract surgery between January 2014 and January 2015 were enrolled and randomly divided into a diquafosol group and a sodium hyaluronate group. INTERVENTION: The diquafosol group used diquafosol 6 times a day and the hyaluronate group used sodium hyaluronate 6 times a day after cataract surgery. MAIN OUTCOME MEASURES: Evaluations of efficacy were conducted based on an Ocular Surface Disease Index questionnaire, tear breakup time (TBUT), Schirmer I test, corneal fluorescein and conjunctival lissamine green staining scores, serial measurement of ocular higher-order aberrations (HOAs), corneal HOAs, and uncorrected distance visual acuity test. Safety evaluations were based on anterior chamber inflammation and discontinuation of the eye drops. RESULTS: Objective signs and subjective symptoms were aggravated at 1 week postoperatively and began to recover significantly 4 weeks after surgery. The diquafosol group showed significantly superior TBUT (P<.001), corneal fluorescein (P=.045), and conjunctival staining (P=.001) compared to the sodium hyaluronate group throughout the study period. TBUT (P<.001) and the change in HOAs (P=.018) recovered significantly more quickly in the diquafosol group. The safety evaluations showed no intergroup differences. CONCLUSIONS: Eye drops of 3% diquafosol may be an effective and safe treatment for the management of cataract surgery-induced dry eye aggravation in patients with preexisting dry eye. (C) 2016 by Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Ophthalmology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9317)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.